Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 6NETWORK 6NIH 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Pancreatic Neoplasms 13Neoplasm Metastasis 10Neoplasms 8Lung Neoplasms 6Colorectal Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Melanoma 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Pancreas Adenocarcinoma 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × Taxes × Clear all
NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡